In this study, intrathecal injection of the specific MOR antagonist CTAP majorly (approximately 60%) inhibited subcutaneous dezocine (1 and 3 mg/kg)-induced mechanical antiallodynia in neuropathy, consistent with the reported MOR antagonists naltrexone and β-funaltrexamine that attenuated dezocine antinociception in the rat tail-withdrawal assay17, 18, although high doses of naloxone and β-funaltrexamine were unable to antagonize its rate decreasing effect in pigeons19. Here, OPRM1 is linked to neuropathy.